Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous nivolumab in advanced solid tumors
NCT03656718Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, open-label trial of nivolumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma and 3 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Serum Nivolumab Concentration at 21 days, Time Taken to Reach Maximum Concentration at 21 days and 3 more. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanomahepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03656718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656718.